Pharvaris (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan Sells 6,888 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 6,888 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $35.05, for a total transaction of $241,424.40. Following the sale, the director directly owned 345,879 shares in the company, valued at $12,123,058.95. The trade was a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Tuesday, June 30th, Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock. The shares were sold at an average price of $35.49, for a total transaction of $1,089,968.88.
• On Thursday, April 30th, Johannes Gerardus Chri Schikan sold 29,070 shares of Pharvaris stock. The stock was sold at an average price of $30.32, for a total transaction of $881,402.40.
• On Wednesday, April 29th, Johannes Gerardus Chri Schikan sold 3,830 shares of Pharvaris stock. The stock was sold at an average price of $30.07, for a total transaction of $115,168.10.
• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total value of $3,003.00.
• On Wednesday, April 22nd, Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total value of $210,350.00.

Pharvaris Stock Down 1.8%

Shares of NASDAQ PHVS traded down $0.63 during trading on Wednesday, reaching $33.95. The company had a trading volume of 376,128 shares, compared to its average volume of 409,202. The stock has a market cap of $2.22 billion, a P/E ratio of -10.68 and a beta of -2.34. The company’s fifty day moving average price is $30.90 and its 200-day moving average price is $28.21. Pharvaris N.V. has a 12 month low of $17.05 and a 12 month high of $35.90.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. As a group, equities analysts predict that Pharvaris N.V. will post -3.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on PHVS shares. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Wall Street Zen upgraded shares of Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Wedbush increased their price target on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. HC Wainwright reissued a “buy” rating on shares of Pharvaris in a research note on Tuesday, June 16th. Finally, Morgan Stanley upped their target price on Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a research report on Thursday, June 25th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Pharvaris currently has a consensus rating of “Moderate Buy” and an average target price of $49.64.

Institutional Investors Weigh In On Pharvaris

A number of large investors have recently bought and sold shares of PHVS. General Atlantic L.P. raised its holdings in shares of Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after purchasing an additional 500,000 shares during the period. Foresite Capital Management IV LLC grew its stake in shares of Pharvaris by 8.3% in the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after buying an additional 368,000 shares during the period. venBio Partners LLC increased its position in Pharvaris by 8.2% in the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after buying an additional 350,000 shares in the last quarter. Deerfield Management Company L.P. increased its position in Pharvaris by 21.1% in the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after buying an additional 425,000 shares in the last quarter. Finally, Commodore Capital LP raised its stake in Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after buying an additional 507,043 shares during the period.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.